Keywordshuman; HTLV-I infections; T-lymphotrophic virus 1; leukemia-lymphoma; adult T-cell; microRNAs; virus replication; cell line; cell transformation; gene expression regulation; HTLV-1/2; proviral load; Western blot; indeterminate; mutations; HTLV-1 infection; risk factors; blood donors; Mashhad; Iran; BLV; HTLV-1; Tax; microRNA; vaccine; HDAC; adult T cell leukemia/lymphoma; HTLV-1; humanized mouse models; oncogenesis; human T-cell leukemia virus type 1; adult T-cell leukemia; HTLV-1 bZip Factor; Valproate; adult T-cell leukemia/lymphoma; allogeneic hematopoietic stem cell transplantation; graft-versus-host disease; mogamulizumab; chemotherapy; antiviral therapy; J0101; Human T-lymphotropic virus type-1 (HTLV-1); immune response; autoimmunity; HTLV-1; PRMT5; transformation; ATLL; Tax; HBZ; p30; lymphoma; deltaretrovirus; antiretroviral; lentivirus; HBZ; HTLV-1; ATL; HTLV-1; HIV-1; HCV; genetic factors; human; HTLV-1; intestinal barrier; retrovirus; breastfeeding; HTLV-I; NOG mice; neutralizing monoclonal antibody; envelope gp46; passive immunity; HTLV-1 Rex; pro-viral expression; unspliced RNA; NMD; alternative splicing; cell cycle regulation; HTLV-1; Tax; p8; virus transmission; cell-to-cell transmission; cell-cell contacts; virological synapse; viral biofilm; cellular conduit; deltaretrovirus; lentivirus; virus assembly; HTLV-1 2; provirus 3; retroviral latency; HTLV-I; Tax; heat shock; adult T cell leukemia (ATL); human immunodeficiency virus (HIV); human T-cell lymphotropic virus type 1 (HTLV-1); human papilloma virus (HPV); retrovirus; liquid based cytology (LBC); invasive cervical cancer (ICC); proviral DNA; PCR
